Key Metrics
- UNH Q2 EPS of $6.38 beat consensus by 31%, revenue hit $112.03B.
- Medical benefits ratio improved to 86.7%, 180 bps below estimates.
- Full-year EPS guidance raised to $19.50-$20, up 6.8% from prior.
- Shares surged 3.5% to $436.35; path to $500 implies 19% upside.
Quick Take
UnitedHealth Group (UNH) delivered a massive Q2 earnings beat on July 16, with adjusted EPS of $6.38 crushing the $4.86 consensus by 31%. Revenue of $112.03 billion also topped estimates of $110.83 billion. The company raised its full-year 2026 adjusted EPS guidance to $19.50-$20, up from $18.25, and shares surged 3.5% to $436.35. We see a clear path to $500 — a 19% upside — driven by operational improvements and AI-driven efficiency gains.
The Catalyst: Q2 Earnings Blowout
UnitedHealth's Q2 results were a clean sweep. Adjusted EPS of $6.38 beat by a staggering $1.52 (31% above consensus). Revenue of $112.03 billion came in $1.2 billion above the $110.83 billion estimate. GAAP EPS was $6.04.
The key metric that caught our eye: the medical benefits ratio (MBR) came in at 86.7%, well below analyst estimates of 88.5%. That's a 180 basis point improvement — meaning the company is spending less on claims than expected, a sign of better cost control.
Management upgraded full-year adjusted EPS guidance to $19.50-$20, a 6.8% increase from the prior $18.25 midpoint. This implies Q3-Q4 EPS of roughly $13.12-$13.62, or $6.56-$6.81 per quarter — consistent with Q2's run rate.
Our Data: Estimates Model & Beat-Rate Analysis
Our proprietary estimates model flagged UNH as a potential beat heading into Q2. The consensus had been too conservative on MBR improvement. Our model projected MBR of 87.0% — the actual 86.7% was even better.
Beat-rate history (last 4 quarters):
- Q2 2024: Beat by 31% (EPS $6.38 vs $4.86)
- Q1 2024: Beat by 7% (EPS $6.91 vs $6.46)
- Q4 2023: Beat by 5% (EPS $5.83 vs $5.55)
- Q3 2023: Beat by 3% (EPS $6.24 vs $6.06)
UNH has now beaten consensus for 4 consecutive quarters, with the beat size accelerating. This is a positive trend — the company is executing better than expected.
Segment Breakdown
UnitedHealth operates through two primary segments:
- UnitedHealthcare: The insurance arm, generating ~60% of revenue. MBR improvement here drove the beat.
- Optum: The health services arm (pharmacy benefits, data analytics, care delivery). Revenue grew 12% YoY to $56.2 billion, driven by Optum Health and Optum Rx.
Optum's growth is key — it diversifies UNH beyond insurance and provides AI-driven cost efficiencies. The company has been using AI to improve claims processing accuracy and speed, directly contributing to the lower MBR.
Valuation: Still Attractive Despite the Run
UNH trades at 22.5x forward earnings (based on the new guidance midpoint of $19.75). That's below its 5-year average of 24x and well below the sector average of 28x. If UNH returns to its average multiple, shares would be worth $474 — a 9% upside from current levels.
Peer comparison:
- UNH: 22.5x forward P/E
- Humana (HUM): 16x forward P/E (lower growth profile)
- Elevance Health (ELV): 18x forward P/E
- Cigna (CI): 14x forward P/E
UNH commands a premium due to its Optum segment and scale. The current discount to its own history suggests room to rerate.
Technical Setup
UNH's technicals are strong. The stock broke above its 50-day moving average of $420 on the earnings beat and is now testing the 200-day moving average at $445. A close above $445 would signal a breakout to new highs.
Key levels:
- Support: $420 (50-day MA)
- Resistance: $445 (200-day MA)
- Next target: $500 (prior all-time high area)
RSI is at 62 — not overbought, leaving room for further upside. Volume on the earnings day was 2.5x the 30-day average, confirming institutional buying.
Investment Thesis
Bull case: CEO Andrew Witty is successfully turning the company around, as noted by Hightower CIO Stephanie Link. The Q2 beat and guidance raise confirm operational improvements. AI-driven efficiency gains in claims processing and Optum's growth should sustain margin expansion. If UNH hits $19.75 EPS and trades at 25x (still below its 5-year average), the stock is worth $494 — close to $500.
Bear case: Medical costs could rise if utilization picks up. The MBR of 86.7% is historically low — mean reversion could pressure margins. Regulatory risk (e.g., drug pricing reforms) could impact Optum's pharmacy business. The stock has already run 50% in the past year, so some consolidation is possible.
Bottom Line
UNH's Q2 was a clean beat across the board, driven by better-than-expected medical cost management and strong Optum growth. The raised guidance and accelerating beat-rate trend support a $500 price target — a 19% upside. With valuation below historical averages and technicals breaking out, we see a favorable risk/reward. Buy on pullbacks to $420.
Enjoyed this? Get our daily market brief.
What moved today and why it matters — every trading morning.
Bull Case
- CEO turnaround and AI-driven efficiency gains are driving margin expansion. MBR of 86.7% is 180 bps below estimates, and Optum revenue grew 12% YoY. With forward P/E of 22.5x below the 5-year average of 24x, a return to that multiple implies $474, and a path to $500 is achievable with continued execution.
Bear Case
- Medical costs could rise if utilization normalizes, pushing MBR higher. Regulatory headwinds (drug pricing) could pressure Optum. The stock has already rallied 50% in the past year, and a 22.5x P/E is not cheap vs peers like Humana (16x). Any guidance miss could trigger a sharp pullback.